优化心血管 - - 代谢综合征的护理:利用实施科学在通向药物公平的道路上
Regina M Longley1, Cecilia Katzenstein1, Dinushika Mohottige2,3
1Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Current cardiology reports
|August 12, 2025
概括
获得心血管--代谢综合征 (CKM) 治疗的机会是不平等的,性别,种族和种族之间存在差异. 解决成本和分散护理等障碍对于实现药物公平至关重要.
科学领域:
- 心血管医学 心血管医学
- 腎臟病學 (nephrology) 是一種醫學專業.
- 代谢障碍 代谢障碍 代谢障碍
- 健康 公平 卫生 公平
- 实施科学 实施科学
背景情况:
- 心血管 - - 代谢 (CKM) 综合征显著导致发病率和死亡率,构成公共卫生挑战.
- 尽管有可用的基于证据的疗法,但对CKM综合征治疗的不平等接入仍然存在.
- 在性别,种族和种族之间,治疗机会的不平等是明显的.
研究的目的:
- 概述心血管--代谢 (CKM) 综合征中药物公平的当前情况.
- 识别阻碍公平获得CKM综合征治疗的障碍.
- 提出改善CKM综合征管理中的药物公平性的策略.
主要方法:
- 文献综述和关于CKM综合征和药物公平性的当前研究的综合.
- 分析治疗机会中发现的差异.
- 讨论障碍,包括多病症,多药,意识,临床惯性,成本,药房准入,社会背景因素和分散的护理.
- 对CKM股权实施科学方法的探索.
主要成果:
- CKM综合征是心血管疾病负担的主要驱动因素.
- 在使用针对CKM综合征的指南导向疗法方面,基于性别,种族和种族存在显著的差异.
- 多个个体和系统障碍阻碍了公平的CKM管理,特别是对于少数群体.
结论:
- 对CKM综合征治疗的不平等获取需要紧急关注和政策改革.
- 需要多方面的,多层次的策略来解决CKM药品公平性.
- 跨学科的护理和实施科学信息的工具可以帮助打击CKM综合征管理中的不平等.
相关概念视频
01:29Cardiomyopathy V: Interprofessional Care
33
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
33
01:30Heart Failure V: Medical Management
23
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
23
01:28Chronic Kidney Disease III: Interprofessional Care
80
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
80
01:18Chronic Kidney Disease IV: Nursing Management
55
Nursing management is essential for preventing complications, maintaining stability, and improving patients' quality of life in chronic kidney disease (CKD). By using a structured approach, nurses help slow CKD progression and support effective patient care.1. Comprehensive patient assessmentEffective management begins with nurses reviewing the patient’s medical history, and identifying key risk factors like diabetes, hypertension, and nephrotoxic drug use. Nurses assess signs of...
55
01:20Acute Kidney Injury V: Interprofessional Care
44
Acute Kidney Injury (AKI) requires a collaborative healthcare approach to restore renal function and prevent complications. Essential management strategies involve monitoring fluid and electrolyte balance, adjusting medications, initiating dialysis when necessary, and providing nutritional support.Fluid and Electrolyte ManagementFluid Monitoring: Regularly monitoring body weight, central venous pressure, and urine output helps detect fluid imbalances early. Patient intake and output are...
44
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
508
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
508